... a clinical-stage biotechnology company focused on development of ... Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium.
News
- Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with ... - AccessWire
- Treadwell Therapeutics Announces A Presentation at the 2022 SABCS Annual Meeting ...
Treadwell Therapeutics, a clinical-stage biotechnology company developing ... Data were presented at the 2022 San Antonio Breast Cancer Symposium ...
- Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients ... - Yahoo Finance
Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on ... Discussion at the 2022 San Antonio Breast Cancer Symposium (SABCS).
- Celcuity (CELC) Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with ...
... Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium.
- Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in ... - BioSpace
Data presented at San Antonio Breast Cancer Symposium® demonstrate preliminary 4-month PFS rate of 44% in ongoing Phase 2 trial in second- or ...